Abbott

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Abbott 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ABT

Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. It operates through the following segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. 

CEO
Robert B. Ford
CEORobert B. Ford
Employees
115,000
Employees115,000
Headquarters
Abbott Park, Illinois
HeadquartersAbbott Park, Illinois
Founded
1888
Founded1888
Employees
115,000
Employees115,000

ABT Key Statistics

Market cap
168.71B
Market cap168.71B
Price-Earnings ratio
31.51
Price-Earnings ratio31.51
Dividend yield
2.54%
Dividend yield2.54%
Average volume
7.96M
Average volume7.96M
High today
$97.99
High today$97.99
Low today
$95.06
Low today$95.06
Open price
$97.35
Open price$97.35
Volume
8.71M
Volume8.71M
52 Week high
$135.37
52 Week high$135.37
52 Week low
$81.97
52 Week low$81.97

Stock Snapshot

With a market cap of 168.71B, Abbott(ABT) trades at $97.51. The stock has a price-to-earnings ratio of 31.51 and currently yields dividends of 2.54%.

On 2026-10-03, Abbott(ABT) stock moved within a range of $95.06 to $97.99. With shares now at $97.51, the stock is trading +2.6% above its intraday low and -0.5% below the session's peak.

Trading activity shows a volume of 8.71M, compared to an average daily volume of 7.96M.

Over the past 52 weeks, Abbott(ABT) stock has traded between a high of $135.37 and a low of $81.97.

Over the past 52 weeks, Abbott(ABT) stock has traded between a high of $135.37 and a low of $81.97.

ABT News

Simply Wall St 20h
Abbott Laboratories Launches SimpleScreen CRC As Fair Value Debate Heats Up

Abbott Laboratories (ABT) just brought SimpleScreen CRC to the U.S. market, adding an FDA-approved, Medicare-covered blood test for colorectal cancer screening...

Abbott Laboratories Launches SimpleScreen CRC As Fair Value Debate Heats Up
TipRanks 1d
Abbott upgraded to Buy from Neutral at Rothschild & Co Redburn

Rothschild & Co Redburn upgraded Abbott (ABT) to Buy from Neutral with a price target of $127, up from $119. The company’s acquisition of Exact Sciences has str...

The Motley Fool 2d
Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026?

As healthcare costs and procedure volumes continue to shift globally, investors must decide between two titans of the industry. Choosing between Abbott Laborato...

Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026?

Analyst ratings

80%

of 30 ratings
Buy
80%
Hold
20%
Sell
0%

More ABT News

Simply Wall St 3d
Abbott Stock May Be 25% Stretched After Biosensor Market Forecast

has seen its share price retreat over the past year, which puts the spotlight squarely on whether the current market value lines up with the cash the business i...

Abbott Stock May Be 25% Stretched After Biosensor Market Forecast
TipRanks 3d
Abbott announces U.S. commercial launch of SimpleScreen CRC

Abbott (ABT) announced the U.S. commercial launch of SimpleScreen CRC, an FDA-approved blood-based colorectal cancer screening test for adults age 45 and older...

People also own

Based on the portfolios of people who own ABT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.